Development of a Preoperative Nomogram Incorporating Biomarkers of Systemic Inflammatory Response to Predict Nonorgan-confined Urothelial Carcinoma of the Bladder at Radical Cystectomy

Lucca, Ilaria; Hofbauer, Sebastian L.; Leitner, Carmen V.; Martino, Michela de; Özsoy, Mehmet; Susani, Martin; Klatte, Tobias

doi:10.1016/j.urology.2016.06.007

Cited by 19 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reported non‐organ‐confined disease and Cho et al . reported intravesical recurrence . Four studies showed a prognostic value of GPS/mGPS in relation to OS or RFS: increased GPS/mGPS was significantly associated with worse prognosis.…”

Section: Serum Protein Markersmentioning

confidence: 99%

“…A summary of six studies investigating the prognostic role of GPS/mGPS in UC is shown in Table . Four studies examined patients with bladder cancer, and two studies examined patients with upper tract UC.…”

Section: Serum Protein Markersmentioning

confidence: 99%

“…A summary of six studies investigating the prognostic role of GPS/mGPS in UC is shown in Table 6. [69][70][71][72][73][74] Four studies 71,73 Four studies showed a prognostic value of GPS/mGPS in relation to OS or RFS: increased GPS/mGPS was significantly associated with worse prognosis. Lucca et al evaluated the association between non-organ-confined disease and several SIR markers including NLR, PLR, MLR, PNI and GPS in patients who underwent radical cystectomy.…”

Section: Gps/mgps In Ucmentioning

confidence: 99%

See 2 more Smart Citations

Role of systemic inflammatory response markers in urological malignancy

Ohno

2018

Int J of Urology

View full text Add to dashboard Cite

The systemic inflammatory response is associated with survival in patients with a variety of cancers. This inflammatory response is measured in the peripheral blood, and can be monitored using two categories of indices: concentration of specific serum proteins (albumin, C‐reactive protein) and differential blood cell count (neutrophils, lymphocytes and platelets). Furthermore, combinations of these indices, such as the Glasgow Prognostic Score, which consists of the serum C‐reactive protein and albumin level; the neutrophil‐to‐lymphocyte ratio; the platelet‐to‐lymphocyte ratio; and the prognostic nutritional index, which is based on peripheral blood lymphocyte count and serum albumin level, have also been evaluated and compared in cancer research. To date, there are hundreds of studies that have shown the prognostic value of systemic inflammatory response markers in patients with urological cancer. Most studies have evaluated the prognostic and predictive role of the pretreatment value of the markers, although some have focused on the role of the post‐treatment value at specific points during the clinical course. The advantages of systemic inflammatory response markers are that they are easily measurable and inexpensive in the clinical setting. However, it is important to consider how clinicians use these markers in clinical practice. The present review provides a concise overview regarding systemic inflammatory markers in urological cancers, specifically C‐reactive protein, Glasgow Prognostic Score/modified Glasgow Prognostic Score, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio and prognostic nutritional index.

show abstract

Section: Serum Protein Markersmentioning

confidence: 99%

Section: Serum Protein Markersmentioning

confidence: 99%

Section: Gps/mgps In Ucmentioning

confidence: 99%

See 1 more Smart Citation

Role of systemic inflammatory response markers in urological malignancy

Ohno

2018

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…Pretreatment measurements of inflammatory markers such as lymphocytes, neutrophils, high-density lipoprotein (HDL), albumin and the C-reactive protein (CRP) have been combined in a variety of scores, indices, and ratios, including the neutrophil-to-lymphocyte ratio (NLR) and the modified Glasgow Prognostic Score (mGPS). Several series showed that the accuracy of prognostic models increased when these markers are added to the clinicopathological features [7,8]. Nevertheless, data regarding the impact of these biomarkers has never been applied to a selected population of elderly patients.…”

Section: Introductionmentioning

confidence: 99%

Oncological impact of inflammatory biomarkers in elderly patients treated with radical cystectomy for urothelial bladder cancer

Mari

Muto

Maida

et al. 2020

Arab Journal of Urology

View full text Add to dashboard Cite

Objective: To evaluate the impact of preoperative markers of systemic inflammation on complications and oncological outcomes in patients aged ≥75 years treated with radical cystectomy (RC) for urothelial bladder cancer (UBC). Patients and methods: The clinical data of 694 patients treated with open RC for UBC at our institution between January 2008 and December 2015 were retrospectively reviewed. Patients aged <75 years, with distant metastases, other-than-urothelial histological type, comorbidities that could affect the systemic inflammatory markers, and patients who received neoadjuvant chemotherapy were excluded. Multivariable regression models were built for the prediction of major postoperative surgical complications, disease recurrence, cancer-specific mortality (CSM), and overall mortality (OM). Results: The median (interquartile range [IQR]) age at surgery was 79 (75-83) years. Major postoperative surgical complications were registered in 41.9% of the patients. The 5-year overall survival, cancer-specific survival and recurrence-free survival rates were 42.4% (95% confidence interval [CI] 34.7-49.9%), 70.3% (95% CI 62.3-76.9%), and 59.8% (95% CI 52.4-66.5), respectively. At multivariable analysis, higher levels of fibrinogen and a modified Glasgow Prognostic Score (mGPS) of 1 and 2 at baseline were independently associated with higher risk of major postoperative complications and of CSM. The inclusion of mGPS and fibrinogen to a standard multivariable model for recurrence and for CSM increased discrimination from 69.4% to 73.0% and from 71.3% to 73.9%, respectively. Preoperative neutrophil-to-lymphocyte ratio of >3 was independently associated with OM (hazard ratio 1.38, 95% CI 1.01-1.77; P = 0.01). Conclusions: In a cohort of elderly patients with UBC treated with RC, fibrinogen and mGPS appeared to be the most relevant prognostic measurements and increased the accuracy of clinicopathological preoperative models to predict major postoperative complications, disease recurrence and mortality.

show abstract

“…LVI definition was provided in 16 studies (48.5%) and was found in 1 069 of 6194 patients (17.3%). Pathological characteristics are reported in Table . Overall, 62% of patients had NMIBC, 32% had cT2 stage and 6% had cT3–4 stage.…”

Section: Evidence Synthesismentioning

confidence: 99%

A systematic review and meta‐analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens

et al. 2018

Self Cite

View full text Add to dashboard Cite

The aim of the present review was to assess the prognostic impact of lymphovascular invasion (LVI) in transurethral resection (TUR) of bladder cancer (BCa) specimens on clinical outcomes. A systematic review and meta-analysis of the available literature from the past 10 years was performed using MEDLINE, EMBASE and Cochrane library in August 2017. The protocol for this systematic review was registered on PROSPERO (Central Registration Depository: CRD42018084876) and is available in full on the University of York website. Overall, 33 studies (including 6 194 patients) evaluating the presence of LVI at TUR were retrieved. LVI was detected in 17.3% of TUR specimens. In 19 studies, including 2 941 patients with ≤cT1 stage only, LVI was detected in 15% of specimens. In patients with ≤cT1 stage, LVI at TUR of the bladder tumour (TURBT) was a significant prognostic factor for disease recurrence (pooled hazard ratio [HR] 1.97, 95% CI: 1.47-2.62) and progression (pooled HR 2.95, 95% CI: 2.11-4.13), without heterogeneity (I = 0.0%, P = 0.84 and I = 0.0%, P = 0.93, respectively). For patients with cT1-2 disease, LVI was significantly associated with upstaging at time of radical cystectomy (pooled odds ratio 2.39, 95% CI: 1.45-3.96), with heterogeneity among studies (I = 53.6%, P = 0.044). LVI at TURBT is a robust prognostic factor of disease recurrence and progression in non-muscle invasive BCa. Furthermore, LVI has a strong impact on upstaging in patients with organ-confined disease. The assessment of LVI should be standardized, reported, and considered for inclusion in the TNM classification system, helping clinicians in decision-making and patient counselling.

show abstract

Development of a Preoperative Nomogram Incorporating Biomarkers of Systemic Inflammatory Response to Predict Nonorgan-confined Urothelial Carcinoma of the Bladder at Radical Cystectomy

Cited by 19 publications

References 26 publications

Role of systemic inflammatory response markers in urological malignancy

Role of systemic inflammatory response markers in urological malignancy

Oncological impact of inflammatory biomarkers in elderly patients treated with radical cystectomy for urothelial bladder cancer

A systematic review and meta‐analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens

Contact Info

Product

Resources

About